Cargando…

Antineoplastics: COVID-19 infection and emergence of ibrutinib resistance in chronic lymphocytic leukaemia: case report

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602495/ http://dx.doi.org/10.1007/s40278-021-05520-8

Ejemplares similares

Ibrutinib induces chromatin reorganisation of chronic lymphocytic leukaemia cells
por: Holmes, Katie B., et al.
Publicado: (2019)

Successful Control of Hepatitis B Virus Reactivation following Restart of Ibrutinib in Chronic Lymphocytic Leukaemia
por: Tjønnfjord, Sara Kristina Viberg, et al.
Publicado: (2021)

Revealing a Phenotypical Appearance of Ibrutinib Resistance in Patients With Chronic Lymphocytic Leukaemia by Flow Cytometry
por: Takács, Ferenc, et al.
Publicado: (2022)

Antineoplastics: Covid-19 infection: 19 case reports
Publicado: (2021)

Exploring the significance of PAK1 through chromosome conformation signatures in ibrutinib‐resistant chronic lymphocytic leukaemia
por: Wu, Zijuan, et al.
Publicado: (2022)

Antineoplastics: COVID-19 infections: 4 case reports
Publicado: (2020)

Antineoplastics/methotrexate: COVID-19 infection: case report
Publicado: (2021)

Antineoplastics: Reactivation of COVID-19 infection: case report
Publicado: (2021)

Antineoplastics: COVID-19 infection: 3 case reports
Publicado: (2022)

Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single‐agent ibrutinib
por: Jones, Jeffrey A., et al.
Publicado: (2017)

Antineoplastics: COVID-19: case report
Publicado: (2021)

Antineoplastics: COVID-19: case report
Publicado: (2021)

Ibrutinib for chronic lymphocytic leukemia in the setting of respiratory failure from severe COVID‐19 infection: Case report and literature review
por: Lin, Adam Yuh, et al.
Publicado: (2020)

Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia
por: Puła, Bartosz, et al.
Publicado: (2019)

Antineoplastics: Covid-19 infection/re-infection: 3 case reports
Publicado: (2021)

Emergence of overt myeloma in a patient with chronic lymphocytic leukemia on ibrutinib therapy
por: Al‐Katib, Ayad M., et al.
Publicado: (2020)

Antineoplastics: Myelosuppression and COVID-19: case report
Publicado: (2020)

Antineoplastics: COVID-19: 11 case reports
Publicado: (2021)

Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia
por: Hansson, Lotta, et al.
Publicado: (2017)

PB1940: REAL-LIFE EXPERIENCE OF THE IMMUNE RECONSTITUTION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA AND SMALL LYMPHOCYTIC LYMPHOMA TREATED WITH IBRUTINIB.
por: Pérez, Belén Olivares, et al.
Publicado: (2023)

Antineoplastics: COVID-19 pneumonia: 7 case reports
Publicado: (2021)

Antineoplastics: Recurrent COVID-19 pneumonia: case report
Publicado: (2021)

Using Genomic Information to Guide Ibrutinib Treatment Decisions in Chronic Lymphocytic Leukaemia: A Cost-Effectiveness Analysis
por: Buchanan, James, et al.
Publicado: (2017)

Long-Term Ibrutinib Therapy Reverses CD8(+) T Cell Exhaustion in B Cell Chronic Lymphocytic Leukaemia
por: Parry, Helen M., et al.
Publicado: (2019)

Isolated central nervous system Aspergillosis infection in a chronic lymphocytic leukemia patient on Ibrutinib: A case report
por: Le, Thuy-Hong, et al.
Publicado: (2020)

Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia
por: Arthurs, Benjamin, et al.
Publicado: (2017)

Cutaneous mucormycosis in a chronic lymphocytic leukemia patient on ibrutinib
por: Sittig, Katherine R., et al.
Publicado: (2021)

Antineoplastics: Various infections: 5 case reports
Publicado: (2019)

Ibrutinib: Aspergillus fumigatus infection, Pseudomonas aeruginosa infection and COVID-19 infection: case report
Publicado: (2022)

Ibrutinib interferes with innate immunity in chronic lymphocytic leukemia patients during COVID-19 infection
por: Fiorcari, Stefania, et al.
Publicado: (2021)

Antineoplastics: Cytopenia and COVID-19 pneumonia: 10 case reports
Publicado: (2021)

Antineoplastics/ciprofloxacin/vancomycin: COVID-19 and anaphylaxis: case report
Publicado: (2022)

Real‐world treatment patterns, adverse events and clinical outcomes in patients with chronic lymphocytic leukaemia treated with ibrutinib in the UK
por: Hillmen, Peter, et al.
Publicado: (2021)

Chimeric Antigen Receptor T Cells Targeting CD19 and Ibrutinib for Chronic Lymphocytic Leukemia
por: Delgado, Julio, et al.
Publicado: (2019)

The role of ibrutinib in COVID-19 hyperinflammation: A case report
por: Maynard, Suzanne, et al.
Publicado: (2021)

Membranous nephropathy in chronic lymphocytic leukemia responsive to ibrutinib: A case report
por: Turcotte, Anna-Eve, et al.
Publicado: (2023)

COVID-19 IN A PATIENT WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN USE OF IBRUTINIB: NOT THAT RISKY?
por: Dourado, M.L.B.F., et al.
Publicado: (2020)

Ibrutinib in Chronic Lymphocytic Leukemia: Clinical Applications, Drug Resistance, and Prospects
por: Zhou, Hong, et al.
Publicado: (2020)

Disseminated Cryptococcal Disease in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib
por: Okamoto, Koh, et al.
Publicado: (2016)

Amebic Encephalitis in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib Therapy
por: Voshtina, Ensi, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_05ja5s9bv57nrc72ugu13on7ar